8-K: SBC Medical Group Launches Tender Offer for Waqoo, Inc.

SBC Medical Group Holdings Incorporated announced a tender offer for up to 575,000 shares of Waqoo, Inc. and an off-market acquisition of 989,802 shares from its CEO, aiming to make Waqoo a consolidated subsidiary.

Summary

• SBC Medical Group Co., Ltd. (SBCMG), a wholly-owned subsidiary of SBC Medical Group Holdings Incorporated, approved the commencement of a tender offer for shares of Waqoo, Inc., a Japanese corporation listed on the Tokyo Stock Exchange Growth Market.
• SBCMG currently owns 353,600 shares of Waqoo, representing approximately 9.49% of Waqoo's outstanding shares.
• Dr. Yoshiyuki Aikawa, the Company's Chief Executive Officer, personally holds 989,802 shares of Waqoo, representing approximately 26.58% of Waqoo's outstanding shares.
• SBCMG will conduct a tender offer for up to 575,000 shares of Waqoo's common stock at a price of JPY 1,900 per share, from November 14, 2025, through December 12, 2025 (20 business days).
• Settlement of the tender offer is expected to take place on December 19, 2025, with SBI Securities Co., Ltd. acting as the tender offer agent.
• Subject to the settlement of the tender offer, SBCMG will acquire all 989,802 shares of Waqoo held by Dr. Aikawa through an off-market transfer at a price of JPY 1,445 per share, pursuant to a share transfer agreement dated November 13, 2025.
• The lower transfer price for Dr. Aikawa's shares reflects the nature of the transaction as a related party transaction.
• Following the completion of both the tender offer and the off-market transfer, SBCMG intends to make Waqoo its consolidated subsidiary, integrating Waqoo into the Company's consolidated group.
• The strategic purpose of the transaction is to accelerate Waqoo's research and development, integrate its advanced technologies and expertise within the SBC Group, enhance offerings in clinical areas like AGA and orthopedics, develop new treatment methods, and strengthen overall competitiveness.
• The companies will also jointly promote the development and implementation of skincare products and leverage Waqoo's processing and research know-how for SBC's international operations, supporting regenerative medicine initiatives.

Sentiment

Score: 7

Explanation: The announcement details a strategic acquisition that aligns with the company's growth objectives and expands its capabilities in key medical areas. The integration of Waqoo's R&D and expertise is a positive step for future competitiveness. The related-party transaction with the CEO, while disclosed, introduces a minor point of scrutiny regarding valuation differences, but the overall strategic intent is positive.

Positives

• Strategic acquisition to integrate Waqoo's research and development initiatives and advanced technologies, enhancing the SBC Group's capabilities.
• Expected to strengthen SBC Group's offerings in clinical areas such as AGA (hair restoration) and orthopedics, and facilitate the development of new treatment methods and proprietary services.
• Aims to strengthen overall competitiveness within the medical industry.
• Enables joint promotion of skincare products, establishing a seamless framework from research to commercialization.
• Waqoo's processing and research know-how is expected to serve as a technological foundation for SBC Medical Group's international operations, supporting joint efforts toward the practical realization of regenerative medicine.
• SBC Medical Group Holdings Incorporated was listed on Nasdaq in September 2024 and selected for inclusion in the Russell 3000 Index in June 2025, indicating strong market recognition and growth trajectory.

Negatives

• The Company's CEO, Dr. Yoshiyuki Aikawa, is selling his 989,802 shares of Waqoo to the subsidiary at JPY 1,445 per share, which is lower than the JPY 1,900 per share offered to other shareholders in the tender offer, explicitly stated as reflecting the nature of a related party transaction.

Risks

• Forward-looking statements are not historical facts and represent only the Company's beliefs regarding future events and performance, many of which are inherently uncertain and outside of the Company's control.
• Actual results may differ materially from current expectations due to various known or unknown risks, uncertainties, and other factors.
• Factors that may cause actual results to differ include changes in global, regional, or local economic, business, competitive, market, and regulatory conditions.
• Other risks are listed under the heading 'Risk Factors' and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (SEC).

Future Outlook

SBC Medical Group aims to integrate Waqoo's advanced technologies and expertise to enhance clinical offerings, develop new treatment methods, strengthen competitiveness, and jointly promote skincare products. Waqoo's know-how is also expected to support SBC's international operations and regenerative medicine initiatives. The company's forward-looking statements reflect current views on product launch plans, strategies, growth in revenue and earnings, and business prospects.

Management Comments

• "SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care."
• "Contributing to the well-being of people around the world through medical innovation."

Industry Context

This acquisition positions SBC Medical Group to expand its capabilities in specialized medical fields like AGA and orthopedics, and to advance into areas like regenerative medicine and clinical skincare product development. It reflects a trend of consolidation and vertical integration in the healthcare and medical technology sectors, where companies seek to acquire specialized expertise to enhance their service offerings and R&D pipelines. SBC's global expansion strategy, particularly in Asia and the US, is further supported by integrating a Japanese-listed company with specific processing and research know-how.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the acquisition terms against industry standards.
• The related-party transaction where the CEO sells shares at a lower price than the tender offer price is a specific detail that would typically warrant scrutiny in corporate governance, though it is explicitly disclosed and explained as reflecting the nature of the transaction.

Corporate Governance

Related Party Transactions

• SBC Medical Group Co., Ltd. (SBCMG) will acquire 989,802 shares of Waqoo, Inc. from Dr. Yoshiyuki Aikawa, the Company's Chief Executive Officer, through an off-market transfer.
• The transfer price for these shares is JPY 1,445 per share, which is lower than the JPY 1,900 per share offered in the concurrent tender offer.
• This price difference is explicitly stated to reflect the nature of the transaction as a related party dealing, where the Tender Offeror acquires shares from a director of its ultimate parent company.
• Dr. Aikawa is deemed a closely related person and a person acting in concert with the Tender Offeror under Japanese accounting regulations.

Stakeholder Impact

• **Shareholders (SBC Medical Group Holdings Incorporated)**: Potential for increased value through strategic acquisition, enhanced R&D capabilities, and expanded market presence. The acquisition cost will impact financials.
• **Shareholders (Waqoo, Inc.)**: Those participating in the tender offer will receive JPY 1,900 per share. Those not participating will become minority shareholders in a consolidated subsidiary.
• **Employees (Waqoo, Inc.)**: Integration into a larger medical group, potentially leading to new opportunities or changes in corporate culture/structure.
• **Customers (SBC Medical Group & Waqoo, Inc.)**: Potential for enhanced and new medical services, treatment methods, and skincare products.

Next Steps

• SBCMG will conduct the Tender Offer from November 14, 2025, through December 12, 2025.
• A Tender Offer Registration Statement will be filed by the Tender Offeror on November 14, 2025.
• Settlement of the Tender Offer is expected on December 19, 2025.
• The off-market transfer of shares from Dr. Aikawa to SBCMG will be executed on December 19, 2025, subject to the completion and settlement of the Tender Offer.
• SBCMG intends to make Waqoo its consolidated subsidiary following the completion of the Tender Offer and the off-market transfer.

Key Dates

Recommendation

The acquisition of Waqoo, Inc. is a clear strategic move for SBC Medical Group, aiming to bolster its R&D, expand clinical offerings, and strengthen its global footprint. This aligns with the company's stated growth objectives and recent market recognition (Nasdaq listing, Russell 3000 inclusion). However, the related-party transaction where the CEO sells his shares at a discount to the tender offer price, while disclosed, introduces a point of consideration regarding internal valuation and governance. While strategically sound, the immediate financial impact and the successful integration of Waqoo remain to be seen. Therefore, a 'hold' recommendation is appropriate for investors to observe the execution and the realization of the anticipated synergies before making further investment decisions.

Keywords

SBC Medical Group, Waqoo Inc., Tender Offer, Acquisition, M&A, Healthcare, Medical Technology, Japan, Tokyo Stock Exchange, Nasdaq, Regenerative Medicine, Clinical Services, Corporate Governance, Related Party Transaction